US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Estrella Immunopharma

1.45

+0.13009.85%

Post-market: 1.25-0.2000-13.79%19:45 EST

Volume:1.08M

Turnover:1.28M

Market Cap:60.95M

PE:-3.94

High:1.47

Open:1.27

Low:0.9700

Close:1.32

52wk High:3.15

52wk Low:0.7301

Shares:42.03M

Float Shares:17.39M

Volume Ratio:0.95

T/O Rate:6.21%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.3677

EPS(LYR):-0.2425

ROE:-268.50%

ROA:-100.93%

PB:-6.20

PE(LYR):-5.98

Loading ...

Overview Company News Filings

Estrella Immunopharma Unveils Phase 1 STARLIGHT-1 Data for EB103 in Aggressive B-Cell Lymphoma

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 Starlight-1 Data for Eb103 at the 2026 Tandem Meetings of Astct® & Cibmtr®

THOMSON REUTERS

Estrella Immunopharma Is Maintained at Buy by D. Boral Capital

Estrella Immunopharma Receives Nasdaq Non-Compliance Notice

Estrella Immunopharma Faces Nasdaq Delisting Risk Over Missed Annual Meeting

Estrella Immunopharma Closes $8 Million Offering With Issuance of Shares and Warrants

Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement

THOMSON REUTERS

Estrella Immunopharma Raises $8 Million in Private Placement of Shares and Warrants

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS

Estrella Immunopharma Files for Secondary Offering

MT Newswires Live

Estrella Immunopharma Inc - Offers up to 2,541,206 Shares for Resale by the Selling Stockholders - SEC Filing

THOMSON REUTERS

BRIEF-Estrella Advances Starlight-1 Trial Into Phase II Following Positive DSMB Recommendation

Estrella Advances Starlight-1 Trial Into Phase Ii Following Positive Dsmb Recommendation

THOMSON REUTERS

Estrella Immunopharma Advances EB103 T-Cell Therapy to Phase II After Positive Safety Review

Estrella Immunopharma Reports 100% Complete Response Rate in STARLIGHT-1 EB103 Trial Cohort

Estrella Immunopharma Is Maintained at Buy by D. Boral Capital

Estrella Immunopharma completes second dose cohort in STARLIGHT-1 trial

Estrella Immunopharma Reports 100% Complete Response Rate in Phase I EB103 Trial for Advanced B-Cell NHL

Estrella Immunopharma Inc - Study Achieves 100% Complete Response Rate at Month 1

THOMSON REUTERS

Estrella Immunopharma Inc - No Serious Adverse Events Reported in Study Phase

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ESLA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ESLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ESLA\",,,,,undefined,":{"symbol":"ESLA","market":"US","secType":"STK","nameCN":"Estrella Immunopharma","latestPrice":1.45,"timestamp":1770411600000,"preClose":1.32,"halted":0,"volume":1079568,"hourTrading":{"tag":"盘后","latestPrice":1.25,"preClose":1.45,"latestTime":"19:45 EST","volume":39989,"amount":52428.721,"timestamp":1770425135350,"change":-0.2,"changeRate":-0.137931,"amplitude":0.132414},"delay":0,"changeRate":0.0984848484848484,"floatShares":17391600,"shares":42034200,"eps":-0.367652,"marketStatus":"Market Closed","change":0.13,"latestTime":"02-06 16:00:00 EST","open":1.27,"high":1.47,"low":0.97,"amount":1278770.427144,"amplitude":0.378788,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.367652,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.32,"preHourTrading":{"tag":"盘前","latestPrice":1.31,"preClose":1.32,"latestTime":"09:27 EST","volume":32069,"amount":40175.0041644,"timestamp":1770388031523,"change":-0.01,"changeRate":-0.007576,"amplitude":0.104848},"postHourTrading":{"tag":"盘后","latestPrice":1.25,"preClose":1.45,"latestTime":"19:45 EST","volume":39989,"amount":52428.721,"timestamp":1770425135350,"change":-0.2,"changeRate":-0.137931,"amplitude":0.132414},"volumeRatio":0.952385},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ESLA\",,,,,undefined,":{"symbol":"ESLA","floatShares":17391600,"roa":"-100.93%","roe":"-268.50%","lyrEps":-0.242472,"volumeRatio":0.952385,"shares":42034200,"dividePrice":0,"high":1.47,"amplitude":0.378788,"preClose":1.32,"low":0.97,"week52Low":0.7301,"pbRate":"-6.20","week52High":3.15,"institutionHeld":0,"latestPrice":1.45,"eps":-0.367652,"divideRate":0,"volume":1079568,"delay":0,"ttmEps":-0.367652,"open":1.27,"prevYearClose":1.56,"prevWeekClose":1.12,"prevMonthClose":1.12,"prevQuarterClose":1.56},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ESLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"ESLA","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-0.13},{"market":"US","date":"2025-08-12","symbol":"ESLA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ESLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ESLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1739941200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ESLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ESLA","date":"2026-02-05","current":-3.943947,"percent":0.891071,"low":-10.568666,"twenty":-5.494176,"median":-4.445625,"eighty":-3.641064,"high":-2.54331,"avg":-4.672711,"sd":1.312543,"marketCap":43715597},"quantilePoints":[{"date":"2023-10-13","current":-4.972461,"twenty":-6.796753,"median":-5.384194,"eighty":-5.200498,"marketCap":55265934},{"date":"2023-10-20","current":-4.346628,"twenty":-5.624899,"median":-4.845774,"eighty":-4.503973,"marketCap":48310170},{"date":"2023-10-27","current":-4.814103,"twenty":-5.358857,"median":-4.766595,"eighty":-4.395592,"marketCap":53505872},{"date":"2023-11-03","current":-4.877446,"twenty":-5.358857,"median":-4.877446,"eighty":-4.546793,"marketCap":54209897},{"date":"2023-11-10","current":-4.085653,"twenty":-5.257507,"median":-4.829938,"eighty":-4.367404,"marketCap":45409589},{"date":"2023-11-17","current":-3.800607,"twenty":-5.219501,"median":-4.560729,"eighty":-4.142662,"marketCap":42241478},{"date":"2023-11-24","current":-4.914497,"twenty":-5.067477,"median":-4.560729,"eighty":-4.117325,"marketCap":49633737},{"date":"2023-12-01","current":-5.785861,"twenty":-5.257507,"median":-4.829938,"eighty":-4.244012,"marketCap":58434045},{"date":"2023-12-08","current":-4.18255,"twenty":-5.193333,"median":-4.719087,"eighty":-4.244012,"marketCap":42241478},{"date":"2023-12-15","current":-4.356823,"twenty":-5.067477,"median":-4.653087,"eighty":-4.244012,"marketCap":44001540},{"date":"2023-12-22","current":-4.321969,"twenty":-5.053915,"median":-4.560729,"eighty":-4.244012,"marketCap":43649527},{"date":"2023-12-29","current":-4.008277,"twenty":-5.005043,"median":-4.502348,"eighty":-4.203463,"marketCap":40481416},{"date":"2024-01-05","current":-4.043132,"twenty":-4.967839,"median":-4.461387,"eighty":-4.18255,"marketCap":40833429},{"date":"2024-01-12","current":-3.520313,"twenty":-4.949351,"median":-4.397024,"eighty":-4.086666,"marketCap":35553244},{"date":"2024-01-19","current":-3.555168,"twenty":-4.949351,"median":-4.37517,"eighty":-4.043132,"marketCap":35905256},{"date":"2024-01-26","current":-4.217405,"twenty":-4.914497,"median":-4.391678,"eighty":-4.043132,"marketCap":42593490},{"date":"2024-02-02","current":-4.217405,"twenty":-4.914497,"median":-4.356823,"eighty":-4.022309,"marketCap":42593490},{"date":"2024-02-09","current":-4.008626,"twenty":-4.879642,"median":-4.356475,"eighty":-4.008626,"marketCap":40484936},{"date":"2024-02-16","current":-3.79915,"twenty":-4.877446,"median":-4.314662,"eighty":-4.008277,"marketCap":38369342},{"date":"2024-02-23","current":-4.421106,"twenty":-4.852108,"median":-4.351551,"eighty":-4.008277,"marketCap":36976978},{"date":"2024-03-01","current":-4.46488,"twenty":-4.845774,"median":-4.356823,"eighty":-4.008556,"marketCap":37343087},{"date":"2024-03-08","current":-4.683308,"twenty":-4.845774,"median":-4.37517,"eighty":-4.008626,"marketCap":39169969},{"date":"2024-03-15","current":-4.508653,"twenty":-4.845774,"median":-4.391678,"eighty":-4.019572,"marketCap":37709196},{"date":"2024-03-22","current":-4.727519,"twenty":-4.845774,"median":-4.421106,"eighty":-4.038967,"marketCap":39539739},{"date":"2024-03-28","current":-5.471666,"twenty":-4.878324,"median":-4.421106,"eighty":-4.043132,"marketCap":45763587},{"date":"2024-04-05","current":-4.990159,"twenty":-4.946386,"median":-4.434042,"eighty":-4.068645,"marketCap":41736391},{"date":"2024-04-12","current":-4.771293,"twenty":-4.947572,"median":-4.461387,"eighty":-4.088693,"marketCap":39905848},{"date":"2024-04-19","current":-4.508653,"twenty":-4.946386,"median":-4.46488,"eighty":-4.106683,"marketCap":37709196},{"date":"2024-04-26","current":-4.552426,"twenty":-4.946123,"median":-4.508653,"eighty":-4.135548,"marketCap":38075304},{"date":"2024-05-03","current":-4.604954,"twenty":-4.927077,"median":-4.543309,"eighty":-4.168608,"marketCap":38514635},{"date":"2024-05-10","current":-4.683746,"twenty":-4.914497,"median":-4.525981,"eighty":-4.18255,"marketCap":39173630},{"date":"2024-05-17","current":-6.309978,"twenty":-4.927077,"median":-4.552426,"eighty":-4.18255,"marketCap":38441413},{"date":"2024-05-24","current":-6.009503,"twenty":-4.949351,"median":-4.552645,"eighty":-4.18255,"marketCap":36610870},{"date":"2024-05-31","current":-5.254478,"twenty":-5.016423,"median":-4.56334,"eighty":-4.196492,"marketCap":32011137},{"date":"2024-06-07","current":-5.573329,"twenty":-5.126143,"median":-4.595762,"eighty":-4.217405,"marketCap":33953631},{"date":"2024-06-14","current":-5.672448,"twenty":-5.245388,"median":-4.604954,"eighty":-4.217405,"marketCap":34557478},{"date":"2024-06-21","current":-5.254478,"twenty":-5.254478,"median":-4.639973,"eighty":-4.217405,"marketCap":32011137},{"date":"2024-06-28","current":-5.553028,"twenty":-5.257507,"median":-4.639973,"eighty":-4.217405,"marketCap":33829952},{"date":"2024-07-05","current":-6.836793,"twenty":-5.380881,"median":-4.661859,"eighty":-4.222726,"marketCap":41650855},{"date":"2024-07-12","current":-8.120557,"twenty":-5.46684,"median":-4.674942,"eighty":-4.245731,"marketCap":49471758},{"date":"2024-07-15","current":-8.478817,"twenty":-5.484657,"median":-4.679369,"eighty":-4.24745,"marketCap":51654336},{"date":"2024-08-02","current":-10.568666,"twenty":-5.500483,"median":-4.681339,"eighty":-4.24917,"marketCap":64386038},{"date":"2024-08-09","current":-8.299687,"twenty":-5.526159,"median":-4.683746,"eighty":-4.266453,"marketCap":50563047},{"date":"2024-08-16","current":-8.419107,"twenty":-5.589093,"median":-4.694558,"eighty":-4.282332,"marketCap":51290573},{"date":"2024-08-23","current":-7.881717,"twenty":-5.717813,"median":-4.727519,"eighty":-4.286974,"marketCap":48016706},{"date":"2024-08-30","current":-6.896503,"twenty":-6.017985,"median":-4.738462,"eighty":-4.287114,"marketCap":42014618},{"date":"2024-09-06","current":-6.329258,"twenty":-6.201587,"median":-4.792698,"eighty":-4.288183,"marketCap":38558870},{"date":"2024-09-13","current":-7.045778,"twenty":-6.309738,"median":-4.815066,"eighty":-4.296814,"marketCap":42924025},{"date":"2024-09-20","current":-5.76261,"twenty":-6.309738,"median":-4.815066,"eighty":-4.313201,"marketCap":35106760},{"date":"2024-09-27","current":-5.791271,"twenty":-6.293445,"median":-4.845774,"eighty":-4.331833,"marketCap":35281366},{"date":"2024-10-04","current":-5.494176,"twenty":-6.293445,"median":-4.868142,"eighty":-4.350567,"marketCap":40171894},{"date":"2024-10-11","current":-4.148845,"twenty":-6.216784,"median":-4.858839,"eighty":-4.350567,"marketCap":30335209},{"date":"2024-10-18","current":-4.157755,"twenty":-6.122441,"median":-4.845774,"eighty":-4.288183,"marketCap":30400352},{"date":"2024-10-25","current":-4.212202,"twenty":-6.099645,"median":-4.815066,"eighty":-4.286905,"marketCap":30798452},{"date":"2024-10-31","current":-4.032032,"twenty":-6.085858,"median":-4.815066,"eighty":-4.286835,"marketCap":29481103},{"date":"2024-11-08","current":-3.964716,"twenty":-6.030708,"median":-4.792698,"eighty":-4.245731,"marketCap":28988907},{"date":"2024-11-15","current":-4.157755,"twenty":-6.026467,"median":-4.727519,"eighty":-4.217405,"marketCap":30400352},{"date":"2024-11-22","current":-3.652759,"twenty":-6.001802,"median":-4.723303,"eighty":-4.18255,"marketCap":32209897},{"date":"2024-11-29","current":-4.656782,"twenty":-5.970998,"median":-4.694558,"eighty":-4.18255,"marketCap":41063331},{"date":"2024-12-06","current":-5.005528,"twenty":-5.961427,"median":-4.719087,"eighty":-4.18255,"marketCap":44138559},{"date":"2024-12-13","current":-5.066661,"twenty":-5.907942,"median":-4.727519,"eighty":-4.18255,"marketCap":44677628},{"date":"2024-12-20","current":-4.513181,"twenty":-5.895445,"median":-4.727519,"eighty":-4.18255,"marketCap":39797061},{"date":"2024-12-27","current":-4.800383,"twenty":-5.891211,"median":-4.759354,"eighty":-4.202312,"marketCap":42329601},{"date":"2025-01-03","current":-4.595649,"twenty":-5.831182,"median":-4.759354,"eighty":-4.210222,"marketCap":40524262},{"date":"2025-01-10","current":-4.55421,"twenty":-5.791868,"median":-4.759354,"eighty":-4.214283,"marketCap":40158853},{"date":"2025-01-17","current":-4.808589,"twenty":-5.791868,"median":-4.765324,"eighty":-4.217405,"marketCap":42401960},{"date":"2025-01-24","current":-4.841412,"twenty":-5.791749,"median":-4.765324,"eighty":-4.217405,"marketCap":42691393},{"date":"2025-01-31","current":-4.595239,"twenty":-5.790189,"median":-4.759354,"eighty":-4.217405,"marketCap":40520644},{"date":"2025-02-07","current":-4.718325,"twenty":-5.781211,"median":-4.75438,"eighty":-4.222726,"marketCap":41606019},{"date":"2025-02-14","current":-4.636268,"twenty":-5.75842,"median":-4.727519,"eighty":-4.245731,"marketCap":40882436},{"date":"2025-02-21","current":-6.113309,"twenty":-5.785861,"median":-4.749406,"eighty":-4.252608,"marketCap":53906929},{"date":"2025-02-28","current":-3.938776,"twenty":-5.785861,"median":-4.75438,"eighty":-4.252608,"marketCap":34731981},{"date":"2025-03-07","current":-4.061863,"twenty":-5.76261,"median":-4.727519,"eighty":-4.217405,"marketCap":35817355},{"date":"2025-03-14","current":-4.184949,"twenty":-5.741662,"median":-4.718911,"eighty":-4.212202,"marketCap":36902729},{"date":"2025-03-21","current":-3.781635,"twenty":-5.692164,"median":-4.717095,"eighty":-4.184949,"marketCap":33346319},{"date":"2025-03-28","current":-3.800136,"twenty":-5.672448,"median":-4.683746,"eighty":-4.18255,"marketCap":33646606},{"date":"2025-04-04","current":-3.839558,"twenty":-5.66199,"median":-4.683746,"eighty":-4.157755,"marketCap":33995653},{"date":"2025-04-11","current":-3.717019,"twenty":-5.653341,"median":-4.678332,"eighty":-4.145266,"marketCap":32910685},{"date":"2025-04-17","current":-3.41639,"twenty":-5.652863,"median":-4.673905,"eighty":-4.117991,"marketCap":30248898},{"date":"2025-04-25","current":-3.921251,"twenty":-5.627318,"median":-4.661859,"eighty":-4.100129,"marketCap":34718965},{"date":"2025-05-02","current":-4.656485,"twenty":-5.620962,"median":-4.656633,"eighty":-4.100129,"marketCap":41228771},{"date":"2025-05-09","current":-4.738178,"twenty":-5.614383,"median":-4.656485,"eighty":-4.103875,"marketCap":41952083},{"date":"2025-05-16","current":-3.800286,"twenty":-5.606051,"median":-4.639973,"eighty":-4.100129,"marketCap":33999270},{"date":"2025-05-23","current":-3.448008,"twenty":-5.579539,"median":-4.636268,"eighty":-4.061863,"marketCap":36165589},{"date":"2025-05-30","current":-4.166329,"twenty":-5.561148,"median":-4.636268,"eighty":-4.061535,"marketCap":36888900},{"date":"2025-06-06","current":-4.329714,"twenty":-5.553028,"median":-4.610297,"eighty":-4.04971,"marketCap":38335524},{"date":"2025-06-13","current":-4.125482,"twenty":-5.553028,"median":-4.595762,"eighty":-4.04971,"marketCap":36527244},{"date":"2025-06-20","current":-3.80443,"twenty":-5.54228,"median":-4.595239,"eighty":-4.043395,"marketCap":33684629},{"date":"2025-06-27","current":-3.241128,"twenty":-5.526159,"median":-4.580844,"eighty":-4.026198,"marketCap":33995653},{"date":"2025-07-03","current":-3.034247,"twenty":-5.524015,"median":-4.570132,"eighty":-4.008754,"marketCap":31825718},{"date":"2025-07-11","current":-3.185615,"twenty":-5.515089,"median":-4.55421,"eighty":-4.008277,"marketCap":33413387},{"date":"2025-07-18","current":-2.827711,"twenty":-5.513197,"median":-4.552645,"eighty":-3.966457,"marketCap":29659399},{"date":"2025-07-25","current":-3.273884,"twenty":-5.50782,"median":-4.552426,"eighty":-3.959029,"marketCap":34339226},{"date":"2025-08-01","current":-2.896327,"twenty":-5.494176,"median":-4.538015,"eighty":-3.922458,"marketCap":30379094},{"date":"2025-08-08","current":-2.903223,"twenty":-5.494004,"median":-4.513181,"eighty":-3.885066,"marketCap":30451425},{"date":"2025-08-15","current":-2.639426,"twenty":-5.488988,"median":-4.510917,"eighty":-3.835115,"marketCap":31891232},{"date":"2025-08-22","current":-2.699552,"twenty":-5.46684,"median":-4.508653,"eighty":-3.80035,"marketCap":32617718},{"date":"2025-08-29","current":-2.944966,"twenty":-5.444751,"median":-4.482671,"eighty":-3.7826,"marketCap":35582965},{"date":"2025-09-05","current":-3.313087,"twenty":-5.433608,"median":-4.465996,"eighty":-3.769203,"marketCap":40030836},{"date":"2025-09-12","current":-3.19038,"twenty":-5.427893,"median":-4.461387,"eighty":-3.733631,"marketCap":38548212},{"date":"2025-09-19","current":-3.435793,"twenty":-5.415817,"median":-4.461387,"eighty":-3.662784,"marketCap":41513459},{"date":"2025-09-26","current":-3.527824,"twenty":-5.384194,"median":-4.434042,"eighty":-3.638873,"marketCap":42625427},{"date":"2025-10-03","current":-4.049328,"twenty":-5.384119,"median":-4.421106,"eighty":-3.638873,"marketCap":48926577},{"date":"2025-10-10","current":-3.773237,"twenty":-5.367927,"median":-4.421106,"eighty":-3.650531,"marketCap":45590674},{"date":"2025-10-17","current":-4.940487,"twenty":-5.357776,"median":-4.421106,"eighty":-3.652349,"marketCap":59694131},{"date":"2025-10-24","current":-7.147678,"twenty":-5.384194,"median":-4.430484,"eighty":-3.652759,"marketCap":86362822},{"date":"2025-10-31","current":-7.822566,"twenty":-5.447537,"median":-4.458062,"eighty":-3.652759,"marketCap":94517251},{"date":"2025-11-07","current":-8.466777,"twenty":-5.494176,"median":-4.461387,"eighty":-3.662784,"marketCap":102301025},{"date":"2025-11-14","current":-6.74888,"twenty":-5.526159,"median":-4.46488,"eighty":-3.676173,"marketCap":81544295},{"date":"2025-11-21","current":-4.529504,"twenty":-5.526159,"median":-4.472676,"eighty":-3.681207,"marketCap":61180254},{"date":"2025-11-28","current":-5.899539,"twenty":-5.526159,"median":-4.492666,"eighty":-3.690323,"marketCap":79685392},{"date":"2025-12-05","current":-5.396261,"twenty":-5.526159,"median":-4.508653,"eighty":-3.712136,"marketCap":72887586},{"date":"2025-12-12","current":-5.144622,"twenty":-5.553028,"median":-4.508653,"eighty":-3.730309,"marketCap":69488683},{"date":"2025-12-19","current":-4.417665,"twenty":-5.553028,"median":-4.510917,"eighty":-3.734601,"marketCap":59669630},{"date":"2025-12-26","current":-4.445625,"twenty":-5.536907,"median":-4.508653,"eighty":-3.752515,"marketCap":60047286},{"date":"2026-01-02","current":-4.361745,"twenty":-5.526159,"median":-4.508653,"eighty":-3.764575,"marketCap":58914318},{"date":"2026-01-09","current":-3.970306,"twenty":-5.521871,"median":-4.472676,"eighty":-3.764575,"marketCap":53627136},{"date":"2026-01-16","current":-3.01866,"twenty":-5.514739,"median":-4.46488,"eighty":-3.724653,"marketCap":40773201},{"date":"2026-01-23","current":-2.936814,"twenty":-5.513197,"median":-4.461387,"eighty":-3.683486,"marketCap":39667700},{"date":"2026-01-30","current":-3.360982,"twenty":-5.50782,"median":-4.461387,"eighty":-3.652759,"marketCap":45396966},{"date":"2026-02-05","current":-3.236501,"twenty":-5.494176,"median":-4.445625,"eighty":-3.641064,"marketCap":43715597}],"updateTime":1770435728414},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ESLA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608796458","title":"Estrella Immunopharma Unveils Phase 1 STARLIGHT-1 Data for EB103 in Aggressive B-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2608796458","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608796458?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:02","pubTimestamp":1770123761,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma Inc. announced that clinical data from its ongoing Phase 1 STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma  will be presented at the 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research . The late-breaking oral presentation is scheduled for February 7, 2026, and the abstract will be available on February 4, 2026, via the conference website. Results from the study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via Bus","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL3K4JV1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2608187986","title":"Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 Starlight-1 Data for Eb103 at the 2026 Tandem Meetings of Astct® & Cibmtr®","url":"https://stock-news.laohu8.com/highlight/detail?id=2608187986","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608187986?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123605,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nTUAWRTQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2606157127","title":"Estrella Immunopharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2606157127","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606157127?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:14","pubTimestamp":1769602440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ESLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 28, 2026 07:14 ET (12:14 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA"],"gpt_icon":0},{"id":"2603656896","title":"Estrella Immunopharma Receives Nasdaq Non-Compliance Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2603656896","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603656896?lang=en_us&edition=fundamental","pubTime":"2026-01-14 06:48","pubTimestamp":1768344505,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma ( ($ESLA) ) has issued an announcement. On January 7, 2026, Estrella Immunopharma, Inc. received notice from Nasdaq that it i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/estrella-immunopharma-receives-nasdaq-non-compliance-notice?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/estrella-immunopharma-receives-nasdaq-non-compliance-notice?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESLA","NQmain","BK4139"],"gpt_icon":0},{"id":"2603655804","title":"Estrella Immunopharma Faces Nasdaq Delisting Risk Over Missed Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2603655804","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603655804?lang=en_us&edition=fundamental","pubTime":"2026-01-14 06:22","pubTimestamp":1768342934,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma Inc. has received a notice from the Nasdaq Stock Market indicating non-compliance with Nasdaq Listing Rule 5620, which requires companies to hold an annual meeting of shareholders within a specified timeframe. The company has 45 days to submit a compliance plan and is planning to hold its annual meeting in April 2026 to address the issue. The notice has no immediate effect on the trading or listing of Estrella Immunopharma’s securities, but there is no guarantee Nasdaq will accept the compliance plan or that the company will regain compliance within any granted extension period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL2GC8vJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2601781793","title":"Estrella Immunopharma Closes $8 Million Offering With Issuance of Shares and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2601781793","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601781793?lang=en_us&edition=fundamental","pubTime":"2026-01-07 03:02","pubTimestamp":1767726132,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma Inc. has announced the closing of an $8.0 million registered direct offering and a concurrent private placement with a single healthcare-focused institutional investor. As part of the transaction, the company issued 4,063,290 shares of common stock and 1,000,000 pre-funded warrants. In the concurrent private placement, Estrella Immunopharma also issued common warrants to purchase up to an aggregate of 7,594,935 shares of common stock. The company has agreed to file one or more registration statements with the SEC to cover the resale of the shares of common stock issuable upon exercise of the common warrants.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content us","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL3l1HwK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2601817600","title":"Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2601817600","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601817600?lang=en_us&edition=fundamental","pubTime":"2026-01-07 03:02","pubTimestamp":1767726120,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA3VBTCR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESLAW","ESLA","BK4139"],"gpt_icon":0},{"id":"2601884332","title":"Estrella Immunopharma Raises $8 Million in Private Placement of Shares and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2601884332","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601884332?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:30","pubTimestamp":1767619825,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma Inc. has announced a private placement involving the sale of unregistered securities to a single healthcare-focused institutional investor. The transaction, which is not a public offering and has not been registered under the Securities Act of 1933, includes the sale of pre-funded warrants and PIPE common warrants. These securities may not be resold in the United States without registration or an applicable exemption. The company has agreed to file registration statements to cover the resale of the common stock and shares issuable upon exercise of the warrants, as part of a registration rights agreement with the investor.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the origi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDLbPx4Vn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2601881099","title":"Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2601881099","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601881099?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:30","pubTimestamp":1767619800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUAB9PPNF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2593439747","title":"Estrella Immunopharma Files for Secondary Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2593439747","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593439747?lang=en_us&edition=fundamental","pubTime":"2025-12-23 00:28","pubTimestamp":1766420892,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma  filed a registration statement Monday for a secondary offering of more than 2.5 million common shares by selling stockholders.The company said it will not receive any proceeds from the offering.Shares of Estrella fell more than 1% in recent trading Monday.Price: 1.66, Change: -0.03, Percent Change: -1.78","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2593393414","title":"Estrella Immunopharma Inc - Offers up to 2,541,206 Shares for Resale by the Selling Stockholders  - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2593393414","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593393414?lang=en_us&edition=fundamental","pubTime":"2025-12-22 23:57","pubTimestamp":1766419079,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nFWN3XS0NB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2588882658","title":"BRIEF-Estrella Advances Starlight-1 Trial Into Phase II Following Positive DSMB Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2588882658","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588882658?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:20","pubTimestamp":1764854450,"startTime":"0","endTime":"0","summary":"BRIEF-Estrella Advances Starlight-1 Trial Into Phase II Following Positive DSMB RecommendationDec 4 (Reuters) - Estrella Immunopharma Inc ESLA.O:ESTRELLA ADVANCES STARLIGHT-1 TRIAL INTO PHASE II FOLLO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0CS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2588884402","title":"Estrella Advances Starlight-1 Trial Into Phase Ii Following Positive Dsmb Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2588884402","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588884402?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:01","pubTimestamp":1764853265,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0CS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2588188446","title":"Estrella Immunopharma Advances EB103 T-Cell Therapy to Phase II After Positive Safety Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2588188446","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588188446?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853254,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma Inc. announced that its STARLIGHT-1 clinical trial has advanced to Phase II following a positive recommendation from an independent Data Safety Monitoring Board . The decision was based on safety data from the Phase I dose escalation phase, during which no treatment-related serious adverse events were reported among nine patients, and all evaluable patients in the high-dose cohort achieved a complete response at Month 1. The STARLIGHT-1 trial is evaluating EB103, a CD19-redirected ARTEMIS T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The expansion phase will further assess safety and preliminary efficacy, with results to be collected and used to inform future pivotal trial strategies. Results from the expansion phase have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gener","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDLPfxdQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2581049819","title":"Estrella Immunopharma Reports 100% Complete Response Rate in STARLIGHT-1 EB103 Trial Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2581049819","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581049819?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:18","pubTimestamp":1762467480,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma Inc. announced the successful completion of the second dose cohort in the Phase I portion of its STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS T-cell therapy for patients with advanced B-cell Non-Hodgkin's Lymphomas . According to the company, all evaluable patients in this high-risk group-including those not suitable for commercial CD19 products and one with central nervous system involvement-achieved a 100% complete response rate at Month 1. No treatment-related serious adverse events were reported in this cohort. The results have been announced by the company, and a Data and Safety Monitoring Board will review the cumulative study data to determine the recommended Phase II dose for the trial's expansion phase. Further details are available under clinical trial identifier NCT06343311.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL6zNthp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2580324895","title":"Estrella Immunopharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2580324895","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580324895?lang=en_us&edition=fundamental","pubTime":"2025-11-04 00:32","pubTimestamp":1762187520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ESLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 03, 2025 11:32 ET (16:32 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA"],"gpt_icon":0},{"id":"2580573215","title":"Estrella Immunopharma completes second dose cohort in STARLIGHT-1 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2580573215","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580573215?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:10","pubTimestamp":1762175426,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma (ESLA) announced the completion of the second dose cohort in Phase I portion of its STARLIGHT-1 Phase I/II clinical trial of ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/estrella-immunopharma-completes-second-dose-cohort-in-starlight-1-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/estrella-immunopharma-completes-second-dose-cohort-in-starlight-1-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2580213658","title":"Estrella Immunopharma Reports 100% Complete Response Rate in Phase I EB103 Trial for Advanced B-Cell NHL","url":"https://stock-news.laohu8.com/highlight/detail?id=2580213658","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580213658?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:02","pubTimestamp":1762174976,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma Inc. announced the successful completion of the second dose cohort in the Phase I portion of its STARLIGHT-1 Phase I/II clinical trial of EB103, a CD19-redirected ARTEMIS T-cell therapy for patients with advanced B-cell Non-Hodgkin's Lymphomas . According to the company, the study achieved a 100% complete response rate at Month 1 in all evaluable patients in this cohort, which included individuals with relapsed or refractory B-cell NHL who had failed multiple prior therapies and were considered high-risk, including one patient with central nervous system involvement. No treatment-related serious adverse events were reported. The data from this phase will be reviewed by an independent Data and Safety Monitoring Board to determine the recommended Phase II dose for the expansion phase of the trial. These results have already been announced by the company.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL6m4ZWS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2580721341","title":"Estrella Immunopharma Inc - Study Achieves 100% Complete Response Rate at Month 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2580721341","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580721341?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:00","pubTimestamp":1762174808,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nTUA46JTBL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2580321344","title":"Estrella Immunopharma Inc - No Serious Adverse Events Reported in Study Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2580321344","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580321344?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:00","pubTimestamp":1762174808,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nTUA46JTBL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESLA","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}]}}